Myeloma biology and therapy: Present status and future developments

Hematology/Oncology Clinics of North America

Volumn 11, Issue 1, 1997, Pages 159-172

  Nishimoto, N ^a   Shima, Y ^a   Yoshizaki, K ^a   Kishimoto, T ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0030887696     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70421-4     Document Type: Article

References (86)

1. A. Ahre M. Bjorkholm H. Mellstedt Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: A randomized clinical trial from the Myeloma Group of Central Sweden Cancer Treat Rep 68 1984 1331
2. S. Akira T. Taga T. Kishimoto Interleukin-6 in biology and medicine Adv Immunol 54 1993 1
3. H. Akiyama N. Nakamura S. Nagasaka Hypercalcaemia due to all-trans retinoic acid [letter] Lancet 339 1992 308
4. R. Alexanian M. Dimopoulos The treatment of multiple myeloma N Engl J Med 330 1994 484
5. R. Alexanian M.A. Dimopoulos K. Delasalle B. Barlogie Primary dexamethasone treatment of multiple myeloma Blood 80 1992 887
6. R. Alexanian M.A. Dimopoulos J. Hester Early myeloablative therapy for multiple myeloma Blood 84 1994 4278
7. K.C. Anderson R.M. Jones C. Morimoto Response patterns of purified myeloma cells to hematopoietic growth factors Blood 73 1989 1915
8. K.C. Anderson B.A. Barut J. Ritz Monoclonal antibody–purged autologous bone marrow transplantation therapy for multiple myeloma Blood 77 1991 712
9. K.C. Anderson J. Andersen R. Soiffer Monoclonal antibody–purged bone marrow transplantation therapy for multiple myeloma Blood 82 1993 2568
10. M. Attal J.L. Harousseau A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 225 1996 91
11. M. Attal F. Huguet D. Schlaifer Intensive combined therapy for previously untreated aggressive myeloma Blood 79 1992 1130
12. M.H. Bakkus C. Heirman I. Van-Riet Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation Blood 80 1992 2326
13. B. Barlogie J. Epstein Plasma Cell Myeloma-New Biological Insights and Advances in Therapy Blood 73 1989 865
14. B. Barlogie S. Jagannath Superiority of tendon autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 1997
15. B.A. Barut L.I. Zon M.K. Cochran Role of interleukin 6 in the growth of myeloma-derived cell lines Leuk Res 16 1992 951
16. R. Bataille M. Jourdan X.G. Zhang B. Klein Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias J Clin Invest 84 1989 2008
17. R. Bataille B. Barlogie Z.Y. Lu Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma Blood 86 1995 685
18. L. Bergui M. Schena G. Gaidano Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma J Exp Med 170 1989 613
19. J. Blade A. Lopez-Guillermo D. Tassies Development of aggressive plasma cell leukaemia under interferon-alpha therapy [see comments] Br J Haematol 79 1991 523
20. M. Borset A. Waage O.L. Brekke E. Helseth TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line Eur J Haematol 53 1994 31
21. F. Caligaris-Cappio L. Bergui M.G. Gregoretti Role of bone marrow stromal cells in the growth of human multiple myeloma Blood 77 1991 2688
22. A. Carter S. Merchav I. Silvian-Draxler I. Tatarsky The role of interleukin-1 and tumour necrosis factor–alpha in human multiple myeloma Br J Haematol 74 1990 424
23. M.R. Cooper K. Dear O.R. McIntyre A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: A Cancer and Leukemia Group B study J Clin Oncol 11 1993 155
24. P. Corradini C. Voena M. Astolfi High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting Blood 85 1995 1596
25. F. Cozzolino M. Torcia D. Aldinucci Production of interleukin-1 by bone marrow myeloma cells Blood 74 1989 380
26. J.H. Feyen P. Elford F.E. Di-Padova U. Trechsel Interleukin-6 is produced by bone and modulated by parathyroid hormone J Bone Miner Res 4 1989 633
27. I.R. Garrett B.G. Durie G.E. Nedwin Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells N Engl J Med 317 1987 526
28. V.S. Goldmacher L.A. Bourret B.A. Levine Anti-CD38–blocked ricin: An immunotoxin for the treatment of multiple myeloma Blood 84 1994 3017
29. H. Goto C. Shimazaki T. Tatsumi Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism Leukemia 9 1995 711
30. J. Hardin S. MacLeod I. Grigorieva Interleukin-6 prevents dexamethasone-induced myeloma cell death Blood 84 1994 3063
31. J.L. Harousseau M. Attal M. Divine Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma Blood 85 1995 3077
32. H. Hata H. Matsuzaki K. Takatsuki Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A Acta Haematol 83 1990 133
33. H. Hata H. Xiao M.T. Petrucci Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells Blood 81 1993 3357
34. H. Hata H. Matsuzaki M. Takeya Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders Blood 86 1995 1939
35. T. Hirano K. Yasukawa H. Harada Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin Nature 324 1986 73
36. J.K. Hitzler H. Martinez-Valdez D.B. Bergsagel Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease Blood 78 1991 1996
37. Y. Ishimi C. Miyaura C.H. Jin IL-6 is produced by osteoblasts and induces bone resorption J Immunol 145 1990 3297
38. S. Jagannath D.H. Vesole L. Glenn Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support Blood 80 1992 1666
39. H. Jernberg M. Pettersson T. Kishimoto K. Nilsson Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines [published erratum appears in Leukemia 1991 June 5(6): following 530] Leukemia 5 1991 255
40. H. Jernberg-Wiklund M. Pettersson K. Nilsson Recombinant interferon-gamma inhibits the growth of IL-6–dependent human multiple myeloma cell lines in vitro Eur J Haematol 46 1991 231
41. M. Jourdan X.G. Zhang M. Portier IFN-alpha induces autocrine production of IL-6 in myeloma cell lines J Immunol 147 1991 4402
42. M. Kawano T. Hirano T. Matsuda Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas Nature 332 1988 83
43. M. Kawano H. Tanaka H. Ishikawa Interleukin-1 accelerates autocrine growth of myeloma cells through interleukin-6 in human myeloma Blood 73 1989 2145
44. M. Kawano I. Yamamoto K. Iwato Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma Blood 73 1989 1646
45. T. Kishimoto T. Taga S. Akira Cytokine signal transduction Cell 76 1994 253
46. T. Kishimoto S. Akira M. Narazaki T. Taga Interleukin-6 family of cytokines and gp130 Blood 86 1995 1243
47. B. Klein X.G. Zhang M. Jourdan Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6 Blood 73 1989 517
48. B. Klein J. Wijdenes X.G. Zhang Murine anti–interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia Blood 78 1991 1198
49. R.J. Kreitman C.B. Siegall D.J. FitzGerald Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma Blood 79 1992 1775
50. N. Kurihara D. Bertolini T. Suda IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release J Immunol 144 1990 4226
51. Y. Levy A. Tsapis J.C. Brouet Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines J Clin Invest 88 1991 696
52. H.M. Lokhorst T. Lamme de-Smet M. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures Blood 84 1994 2269
53. Lowik C.W. van-der-Pluijm G. H. Bloys Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis Biochem Biophys Res Commun 162 1989 1546
54. Z.Y. Lu X.G. Zhang C. Rodriguez Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells Blood 85 1995 2521
55. F. Mandelli G. Avvisati S. Amadori Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy N Engl J Med 322 1990 1430
56. H. Mellstedt A. Ahre M. Bjorkholm Interferon therapy in myelomatosis Lancet 1 1979 245
57. A. Miyajima T. Kitamura N. Harada Cytokine receptors and signal transduction Annu Rev Immunol 10 1992 295
58. G.R. Mundy Evidence for the secretion of an osteoclast stimulating factor in myeloma N Engl J Med 291 1974 1041
59. D.M. Nachbaur M. Herold A. Maneschg H. Huber Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: Correlation with disease activity and other prognostic parameters Ann Hematol 62 1991 54
60. R. Niesvizky D.S. Siegel X. Busquets Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma Br J Haematol 89 1995 217
61. N. Nishimoto A. Ogata Y. Shima Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130 J Exp Med 179 1994 1343
62. A. Ogata N. Nishimoto Y. Shima Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction Blood 84 1994 3040
63. Y. Okuno T. Takahashi A. Suzuki Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth Leukemia 5 1991 585
64. A. Osterborg M. Bjorkholm M. Bjoreman Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: A randomized study from the Myeloma Group of Central Sweden Blood 81 1993 1428
65. T.T. Pelliniemi K. Irjala K. Mattila Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group Blood 85 1995 765
66. M. Portier X.G. Zhang E. Caron Gamma-interferon in multiple myeloma: Inhibition of interleukin-6 (IL-6)–dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro Blood 81 1993 3076
67. J.R. Quesada R. Alexanian M. Hawkins Treatment of multiple myeloma with recombinant alpha-interferon Blood 67 1986 275
68. Q.M. Ralph M.J. Brisco D.E. Joshua Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: Evidence from the Ig heavy chain gene Blood 82 1993 202
69. S.E. Salmon B.G. Durie L. Young Effects of cloned human leukocyte interferons in the human tumor stem cell assay J Clin Oncol 1 1983 217
70. K. Sato M. Tsuchiya J. Saldanha Reshaping a human antibody to inhibit the interleukin 6–dependent tumor cell growth Cancer Res 53 1993 851
71. G. Schwab C.B. Siegall L.A. Aarden Characterization of an interleukin-6–mediated autocrine growth loop in the human multiple myeloma cell line, U266 Blood 77 1991 587
72. M. Schwabe A.T. Brini M.C. Bosco Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6–dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains J Clin Invest 94 1994 2317
73. Y. Shima N. Nishimoto A. Ogata Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis Blood 85 1995 757
74. S. Shimizu R. Yoshioka Y. Hirose Establishment of two interleukin 6 (B cell stimulatory factor 2/interferon beta 2)–dependent human bone marrow–derived myeloma cell lines J Exp Med 169 1989 339
75. N. Sidell T. Taga T. Hirano Retinoic acid–induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors J Immunol 146 1991 3809
76. E. Solary M. Guiguet V. Zeller Radioimmunoassay for the measurement of serum IL-6 and its correlation with tumour cell mass parameters in multiple myeloma Am J Hematol 39 1992 163
77. P. Sonneveld M. Schoester de-Leeuw K. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors Br J Haematol 79 1991 589
78. F.K. Stevenson A.J. Bell R. Cusack Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody Blood 77 1991 1071
79. T. Tamura N. Udagawa N. Takahashi Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6 Proc Natl Acad Sci USA 90 1993 11924
80. A. Tienhaara K. Pulkki K. Mattila Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis Br J Haematol 86 1994 391
81. H. Uchiyama B.A. Barut A.F. Mohrbacher Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion Blood 82 1993 3712
82. J.J. Westendorf J.M. Lammert D.F. Jelinek Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines Blood 85 1995 3566
83. X.G. Zhang B. Klein R. Bataille Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma Blood 74 1989 11
84. X.G. Zhang R. Bataille M. Jourdan Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells [see comments] Blood 76 1990 2599
85. X.G. Zhang J.P. Gaillard N. Robillard Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma Blood 83 1994 3654
86. X.G. Zhang J.J. Gu Z.Y. Lu Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130 J Exp Med 179 1994 1337